IBM March 27th Options Begin Trading

The note outlines two IBM options strategies around the current share price of $288.18: a sell-to-open $285 put (bid $10.85) which nets a cost basis of $274.15 and is ~1% OTM with a 56% probability of expiring worthless, representing a 3.81% return (27.81% annualized) if it does. The covered-call example is a sell-to-open $290 call (bid $11.35) against shares bought at $288.18, offering a 4.57% total return to the $290 strike by the March 27 expiration and a 3.94% premium boost (28.78% annualized) with a 49% chance of expiring worthless; implied vols are ~34% (put) and 33% (call) versus a 12-month realized volatility of 30%.

Analysis

Market structure: Option sellers and income-oriented equity holders directly benefit from the current skew — selling the Mar-27 $285 put nets $10.85 (effective buy at $274.15) and yields 3.81% over ~1 month (27.8% annualized). Covered-call sellers collecting $11.35 on the $290 call get 4.57% to a $290 cap but concede upside beyond ~0.6% from here. Dealers and delta-hedgers will supply liquidity; a wave of assignment would convert cash to equity demand and modestly tighten share float in the near term.

Risk assessment: Tail risks include a >10% gap-down from macro shock or a negative surprise from IBM (contract loss, guidance cut) that could vaporize the one-month premium and force unwanted assignment; IV sits ~3–4pp above 12-month realized (33–34% vs 30%), so sellers have a small edge but limited buffer. Near term (days–weeks) trade P&L dominated by IV and macro prints (Fed/GDP); medium term (quarters) driven by IBM fundamentals (AI services wins, margins, buybacks). Hidden dependency: dealer gamma hedging can amplify intraday moves and widen bid/asks.

Trade implications: Direct play — establish cash-secured puts: sell 1x IBM Mar-27 $285 put at $10.85 size 1–3% portfolio (permanent cash reserve ~$28,500 per contract), acceptance only if willing to own at $274.15; set automatic buy-to-close if IBM < $260 or IV > 45%. Covered-income alternative — buy IBM and sell Mar-27 $290 calls collecting $11.35, target 1–2% position for yield. For downside-limited sellers use put spreads: sell 285/270 for net credit ~?$ (limits assignment), or add a cheap protective $270 put if risk-averse.

Contrarian angles: The market underestimates the modestness of the edge — 56%/49% odds give only thin expected return for short-term risk; selling premium is not free alpha, it’s timing-risk dependent. If IBM reports a material contract or M&A, covered-call sellers will underperform materially (left-tail for income sellers). Historical precedent: large-cap tech with recurring buybacks can produce muted downside and make short-term option income attractive — but only if sellers accept assignment risk and 8–12% drawdowns occasionaly.

Key Decisions for Investors

• Sell cash‑secured IBM Mar-27 2026 $285 put at $10.85 (effective buy $274.15) sized to 1–3% of portfolio; commit only if willing to own at that basis; set buy-to-close if IBM trades below $260 or IV > 45%.
• Establish a 1–2% covered‑call income sleeve: buy IBM and sell Mar-27 $290 call at $11.35; roll monthly if unchanged and collect ~3.9% per month boost (~28.8% annualized) while capping upside at $290.
• If risk-averse, execute a 285/270 put spread (sell 285, buy 270) for net credit to limit assignment exposure; target net credit ≥ $6.00 to keep roll/adjust economics attractive over 30–60 days.
• Implement a relative hedge: pair the IBM covered‑call position with a short allocation to QQQ equal to ~0.6x notional to reduce growth‑beta exposure while keeping income profile; rebalance monthly.
• Avoid size expansion >3% until two catalysts pass (next quarterly earnings and next Fed decision); each should be treated as a binary event — reduce position by half 48 hours ahead of earnings if IV spikes >50%.